(Q47217953)

11 January 2018

title

A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside (English)

1 reference

11 January 2018

main subject

phase II clinical trial

0 references

author name string

Paul B Chapman

1

1 reference

11 January 2018

Linda Williams

2

1 reference

11 January 2018

Nadia Salibi

3

1 reference

11 January 2018

Wen-Jen Hwu

4

1 reference

11 January 2018

Susan E Krown

5

1 reference

11 January 2018

Philip O Livingston

6

1 reference

11 January 2018

language of work or name

English

0 references

publication date

1 July 2004

1 reference

11 January 2018

published in

Vaccine

1 reference

11 January 2018

volume

22

1 reference

11 January 2018

issue

21-22

1 reference

11 January 2018

page(s)

2904-2909

1 reference

11 January 2018

Immunogenicity of melanoma-associated gangliosides in cancer patients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.028

Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.028

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.028

Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.028

Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.028

Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.028

10.1016/J.VACCINE.2003.12.028

7 January 2021

Identifiers

DOI

1 reference

11 January 2018

1 reference

11 January 2018